Clinical trials recruiting for Pancreatic Ductal Adenocarcinoma (PDAC)
32
Recruiting trials
32
US states with sites
13
Countries
6%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 12 |
| California | 10 |
| Florida | 9 |
| Maryland | 8 |
| Virginia | 8 |
| Massachusetts | 7 |
| New York | 7 |
| Ohio | 6 |
| Tennessee | 6 |
| Arizona | 4 |
| Colorado | 4 |
| Michigan | 4 |
Top cities
Fairfax, Virginia 8Houston, Texas 8Baltimore, Maryland 7Boston, Massachusetts 7New York, New York 7San Antonio, Texas 7Nashville, Tennessee 6Tampa, Florida 6Dallas, Texas 5Sarasota, Florida 4
Self-screener
Recruiting trials
- A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Advanced Therapies for Liver Metastases
- Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
- Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)
- Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
- Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
- EUS-RFA PANCARDINAL-1 Trial
- Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
- Nutrition Intervention for Pancreatic Cancer
- Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer
- Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
- ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
- RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer
- Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Related conditions
Trials recruiting for Pancreatic Ductal Adenocarcinoma (PDAC) often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Colorectal cancer 1359Non-small cell lung cancer 507Lung cancer 2180Colorectal cancer 50PDAC 11Pancreatic Adenocarcinoma 49PDAC - Pancreatic Ductal Adenocarcinoma 21Pancreatic Cancer Metastatic 16Pancreatic Adenocarcinoma Metastatic 6
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Pancreatic Ductal Adenocarcinoma (PDAC) trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.